公开(公告)号：US20160046713A1

公开(公告)日：2016-02-18

申请号：US14924786

申请日：2015-10-28

Applicant: INNATE PHARMA

Inventor： NICOLAS ANFOSSI ,  LAURENT GAUTHIER ,  YANNIS MOREL ,  ALESSANDRO MORETTA ,  SILVIA PAROLINI ,  BENJAMIN ROSSI

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.

Abstract translation: 本发明提供能够结合KIR3D多肽的抗原结合蛋白。 抗体在治疗特征为表达KIR3DL2的细胞，特别是CD4 + T细胞，包括恶性肿瘤例如真菌病真菌和Sézary综合征的疾病中具有增加的活性。

公开(公告)号：US20150125464A1

公开(公告)日：2015-05-07

申请号：US14594353

申请日：2015-01-12

Applicant: Innate Pharma, S.A. ,  University of Genova

Inventor： ALESSANDRO MORETTA ,  EMANUELA MARCENARO ,  FRANCOIS ROMAGNE ,  PASCALE ANDRE

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/572 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/76 ,  G01N33/56966 ,  G01N2333/70596 ,  G01N2500/04

Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

公开(公告)号：US20150132316A1

公开(公告)日：2015-05-14

申请号：US14594322

申请日：2015-01-12

Applicant: INNATE PHARMA, S.A. ,  UNIVERSITY OF GENOVA

Inventor： ALESSANDRO MORETTA ,  EMANUELA MARCENARO ,  FRANCOIS ROMAGNE ,  PASCALE ANDRE

IPC: C07K16/28 ,  G01N33/569

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/572 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/76 ,  G01N33/56966 ,  G01N2333/70596 ,  G01N2500/04

Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

公开(公告)号：US20130315892A1

公开(公告)日：2013-11-28

申请号：US13912333

申请日：2013-06-07

Applicant: UNIVERSITY OF GENOVA ,  INNATE PHARMA, S.A.

Inventor： ALESSANDRO MORETTA ,  ROBERTA CASTRICONI ,  CHRISTINA BOTTINO ,  LORENZO MORETTA

IPC: A61K39/395

CPC classification number: A61K39/39558 ,  C07K16/2827 ,  C07K16/30 ,  C07K2319/30

Abstract: The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.

Abstract translation: 本发明涉及鉴定作为肿瘤相关分子的4Ig-B7-H3蛋白，其通过NK细胞上的4Ig-B7-H3受体赋予保护免受NK细胞介导的裂解。 本发明提供了干扰可以用于增强NK细胞细胞毒性的4Ig-B7-H3蛋白与其受体之间的相互作用的化合物。 还提供了结合4Ig-B7-H3表达细胞以抑制或消除它们的化合物。 该化合物特别可用于治疗肿瘤，炎性病症，感染和移植。 还提供了通过检测4Ig-B7-H3蛋白来诊断疾病的方法。